MARKETS / BALCAO / GBCS
BALCAO · REAL ESTATE INVESTMENT TRUSTS

Selectis Health, Inc. GBCS

15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$41.4M
▲ 4.9% vs FY2024
EPS · FY25
$-0.34
Dividend / sh · FY25
Payout · FY25
ROE · FY25
Net margin · FY25
-2.5%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 41.4M
Revenue, FY2025 · full 15-year series below
Revenue Net income
0.020.040.060.0-0.0201020142017202020232025
0.020.040.060.0-0.02016201920222025

The company lost 2 cents on every revenue dollar this year.

Per share
USD -0.34
Diluted EPS, FY2025
EPS
0.40.81.2-0.34201020142017202020232025
0.40.81.2-0.342016201920222025

The company pays no cash dividend.

Profitability
Return on equity, FY2025
ROE
4080120160201020142017202020232025
40801201602016201920222025
Operating margin-3.8%
Net margin-2.5%
Return on assets-3.1%

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+14.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.7%
+14.6%
+14.4%
Returned to shareholders
−25.4%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.00B
Shares outstanding, FY2025
0.010.00201020142017202020232025
0.030.002016201920222025
Change, 5 years+14.2%
Change, 10 years

The share count grew 14% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 32.6M
total assets, end of FY2025
Total assetsUSD 32.6M
EquityUSD -6.2M
CashUSD 1.0M
Gross debtUSD 24.3M
Net debtUSD 23.3M
Current ratio0.30×

Net debt stands at -376% of equity.

History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
Income tax $B
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.34
−0.80
−1.31
−0.79
−0.82
0.95
−0.03
−0.08
−0.12
−0.05
−0.15
0.06
−0.26
−0.13
−0.22
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
−13
31
·
·
·
ROE %
·
·
·
−118.2
−69.1
148.3
−98.2
−109.2
−83.5
−21.4
−40.1
17.4
−197.1
−48.5
−79.3
Shares out B
0.00
0.00
0.00
0.00
0.00
0.00
0.03
0.03
0.03
0.03
0.02
0.02
0.01
0.01
0.01

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
40 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed